Cargando…
Intensity Modulated Radiotherapy with Carbon Ion Radiotherapy Boost for Acinic Cell Carcinoma of the Salivary Glands
SIMPLE SUMMARY: Acinic cell carcinoma is a rare disease treated usually by surgery. The role of radiotherapy is controversially discussed. In this retrospective analysis based on 15 patients undergoing postoperative or definitive radiotherapy (intensity-modulated radiotherapy, IMRT) with carbon ion...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795372/ https://www.ncbi.nlm.nih.gov/pubmed/33401730 http://dx.doi.org/10.3390/cancers13010124 |
_version_ | 1783634429570187264 |
---|---|
author | Schmid, Maximilian P. Held, Thomas Lang, Kristin Herfarth, Klaus Hörner-Rieber, Juliane Harrabi, Semi B. Moratin, Julius Freudlsperger, Christian Zaoui, Karim Debus, Jürgen Adeberg, Sebastian |
author_facet | Schmid, Maximilian P. Held, Thomas Lang, Kristin Herfarth, Klaus Hörner-Rieber, Juliane Harrabi, Semi B. Moratin, Julius Freudlsperger, Christian Zaoui, Karim Debus, Jürgen Adeberg, Sebastian |
author_sort | Schmid, Maximilian P. |
collection | PubMed |
description | SIMPLE SUMMARY: Acinic cell carcinoma is a rare disease treated usually by surgery. The role of radiotherapy is controversially discussed. In this retrospective analysis based on 15 patients undergoing postoperative or definitive radiotherapy (intensity-modulated radiotherapy, IMRT) with carbon ion radiotherapy boost leads to excellent results after R1-resection, and is a promising treatment modality in inoperable patients. G1-2 xerostomia, dysgeusia, and trismus were the main reported morbidity symptoms after radiotherapy. Confirmation of the results with larger patient cohorts is needed. ABSTRACT: Aim: to report clinical outcome in patients with acinic cell carcinoma of the salivary glands treated with intensity-modulated radiotherapy (IMRT) and carbon ion radiotherapy (CIRT) boost. Materials and Methods: all patients with acinic cell carcinoma of the salivary glands treated at the Heidelberg Ion-Beam Therapy Center were considered for this retrospective analysis. All patients received a CIRT boost with 18–24 Gy radiobiologic effectiveness (RBE)-weighted dose in 3 Gy RBE-weighted dose per fraction followed by IMRT, with 50–54 Gy in 2 Gy per fraction. Disease outcome was evaluated for local (LR), nodal (NR), distant recurrence (DR), and disease-free (DFS) and overall survival (OS). Morbidity was scored based on Common Terminology Criteria for Adverse Events (CTCAE) version 5. Descriptive statistics and the Kaplan-Meier method were used for analysis. Results: fifteen patients were available for analysis. Median follow-up after radiotherapy was 43 months. Six patients were treated for primary disease and nine for recurrent disease. Eight patients were treated with radiotherapy for macroscopic disease. Disease recurrence was observed in four patients: 1 LR, 2 NR, and 2 DR; 5-year local control, DFS, and OS were 80%, 52%, and 80%, respectively. No radiotherapy-related G3-5 morbidity was observed. Conclusion: In acinic cell carcinoma, IMRT with carbon ion radiotherapy boost leads to excellent results after R1-resection and is a promising treatment modality for definitive treatment in inoperable patients. |
format | Online Article Text |
id | pubmed-7795372 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77953722021-01-10 Intensity Modulated Radiotherapy with Carbon Ion Radiotherapy Boost for Acinic Cell Carcinoma of the Salivary Glands Schmid, Maximilian P. Held, Thomas Lang, Kristin Herfarth, Klaus Hörner-Rieber, Juliane Harrabi, Semi B. Moratin, Julius Freudlsperger, Christian Zaoui, Karim Debus, Jürgen Adeberg, Sebastian Cancers (Basel) Article SIMPLE SUMMARY: Acinic cell carcinoma is a rare disease treated usually by surgery. The role of radiotherapy is controversially discussed. In this retrospective analysis based on 15 patients undergoing postoperative or definitive radiotherapy (intensity-modulated radiotherapy, IMRT) with carbon ion radiotherapy boost leads to excellent results after R1-resection, and is a promising treatment modality in inoperable patients. G1-2 xerostomia, dysgeusia, and trismus were the main reported morbidity symptoms after radiotherapy. Confirmation of the results with larger patient cohorts is needed. ABSTRACT: Aim: to report clinical outcome in patients with acinic cell carcinoma of the salivary glands treated with intensity-modulated radiotherapy (IMRT) and carbon ion radiotherapy (CIRT) boost. Materials and Methods: all patients with acinic cell carcinoma of the salivary glands treated at the Heidelberg Ion-Beam Therapy Center were considered for this retrospective analysis. All patients received a CIRT boost with 18–24 Gy radiobiologic effectiveness (RBE)-weighted dose in 3 Gy RBE-weighted dose per fraction followed by IMRT, with 50–54 Gy in 2 Gy per fraction. Disease outcome was evaluated for local (LR), nodal (NR), distant recurrence (DR), and disease-free (DFS) and overall survival (OS). Morbidity was scored based on Common Terminology Criteria for Adverse Events (CTCAE) version 5. Descriptive statistics and the Kaplan-Meier method were used for analysis. Results: fifteen patients were available for analysis. Median follow-up after radiotherapy was 43 months. Six patients were treated for primary disease and nine for recurrent disease. Eight patients were treated with radiotherapy for macroscopic disease. Disease recurrence was observed in four patients: 1 LR, 2 NR, and 2 DR; 5-year local control, DFS, and OS were 80%, 52%, and 80%, respectively. No radiotherapy-related G3-5 morbidity was observed. Conclusion: In acinic cell carcinoma, IMRT with carbon ion radiotherapy boost leads to excellent results after R1-resection and is a promising treatment modality for definitive treatment in inoperable patients. MDPI 2021-01-02 /pmc/articles/PMC7795372/ /pubmed/33401730 http://dx.doi.org/10.3390/cancers13010124 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Schmid, Maximilian P. Held, Thomas Lang, Kristin Herfarth, Klaus Hörner-Rieber, Juliane Harrabi, Semi B. Moratin, Julius Freudlsperger, Christian Zaoui, Karim Debus, Jürgen Adeberg, Sebastian Intensity Modulated Radiotherapy with Carbon Ion Radiotherapy Boost for Acinic Cell Carcinoma of the Salivary Glands |
title | Intensity Modulated Radiotherapy with Carbon Ion Radiotherapy Boost for Acinic Cell Carcinoma of the Salivary Glands |
title_full | Intensity Modulated Radiotherapy with Carbon Ion Radiotherapy Boost for Acinic Cell Carcinoma of the Salivary Glands |
title_fullStr | Intensity Modulated Radiotherapy with Carbon Ion Radiotherapy Boost for Acinic Cell Carcinoma of the Salivary Glands |
title_full_unstemmed | Intensity Modulated Radiotherapy with Carbon Ion Radiotherapy Boost for Acinic Cell Carcinoma of the Salivary Glands |
title_short | Intensity Modulated Radiotherapy with Carbon Ion Radiotherapy Boost for Acinic Cell Carcinoma of the Salivary Glands |
title_sort | intensity modulated radiotherapy with carbon ion radiotherapy boost for acinic cell carcinoma of the salivary glands |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795372/ https://www.ncbi.nlm.nih.gov/pubmed/33401730 http://dx.doi.org/10.3390/cancers13010124 |
work_keys_str_mv | AT schmidmaximilianp intensitymodulatedradiotherapywithcarbonionradiotherapyboostforaciniccellcarcinomaofthesalivaryglands AT heldthomas intensitymodulatedradiotherapywithcarbonionradiotherapyboostforaciniccellcarcinomaofthesalivaryglands AT langkristin intensitymodulatedradiotherapywithcarbonionradiotherapyboostforaciniccellcarcinomaofthesalivaryglands AT herfarthklaus intensitymodulatedradiotherapywithcarbonionradiotherapyboostforaciniccellcarcinomaofthesalivaryglands AT hornerrieberjuliane intensitymodulatedradiotherapywithcarbonionradiotherapyboostforaciniccellcarcinomaofthesalivaryglands AT harrabisemib intensitymodulatedradiotherapywithcarbonionradiotherapyboostforaciniccellcarcinomaofthesalivaryglands AT moratinjulius intensitymodulatedradiotherapywithcarbonionradiotherapyboostforaciniccellcarcinomaofthesalivaryglands AT freudlspergerchristian intensitymodulatedradiotherapywithcarbonionradiotherapyboostforaciniccellcarcinomaofthesalivaryglands AT zaouikarim intensitymodulatedradiotherapywithcarbonionradiotherapyboostforaciniccellcarcinomaofthesalivaryglands AT debusjurgen intensitymodulatedradiotherapywithcarbonionradiotherapyboostforaciniccellcarcinomaofthesalivaryglands AT adebergsebastian intensitymodulatedradiotherapywithcarbonionradiotherapyboostforaciniccellcarcinomaofthesalivaryglands |